Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
Fausto Petrelli(Azienda Ospedaliera Treviglio), Alberto F. Sobrero(Ospedale Policlinico San Martino), Valeria Pusceddu(University of Cagliari), Gerardo Rosati(Ospedale San Carlo), Monica Ronzoni, Rodolfo Mattioli(Ospedali Riuniti Marche Nord), Vittorina Zagonel(Istituto Oncologico Veneto), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Evaristo Maiello(Casa Sollievo della Sofferenza), Sara Lonardi(Istituto Oncologico Veneto), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Domenico Corsi(Ospedale San Carlo), Lorenza Rimassa(Humanitas University), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Giovanni Gerardo Cardellino(Ospedale Santa Maria della Misericordia di Udine), Andrea Mambrini, Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Roberto Labianca(Ospedale Papa Giovanni XXIII), Fabio Galli(Mario Negri Institute for Pharmacological Research), Maria Banzi(Azienda Ospedaliera S.Maria), Libero Ciuffreda(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Saverio Cinieri(Ospedale A. Perrino)
Cited by 49
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k